First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

BACKGROUND: Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% or <1% in Part 1 of CheckMa...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Byrne, K.J., Lee, K.H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J.-H., Daga, H., Yu, C.-J., Hotta, K., Tanaka, H., Takeda, M., Yokoyama, T., Nathan, F.E., Lee, J.-S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864530/
https://www.ncbi.nlm.nih.gov/pubmed/35158207
http://dx.doi.org/10.1016/j.esmoop.2022.100394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864530/
https://www.ncbi.nlm.nih.gov/pubmed/35158207
http://dx.doi.org/10.1016/j.esmoop.2022.100394

Ejemplares similares